A phase II evaluation of karenitecin (IND 57250) in the third-Line treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

Trial Profile

A phase II evaluation of karenitecin (IND 57250) in the third-Line treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Cositecan (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2008 Actual study completion date is Jul 2008 as reported by ClinicalTrials.gov.
    • 06 Aug 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 17 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top